MIRA

MIRA Pharmaceuticals, Inc. - 10-Q Summary (Q3 2024)

Business Context and Reporting Period

MIRA Pharmaceuticals, Inc. (MIRA) is a pre-clinical-stage pharmaceutical development company focused on two neuroscience programs: Ketamir-2, an oral ketamine analog for treatment-resistant depression and neuropathic pain, and MIRA-55, an oral pharmaceutical marijuana candidate for neuropathic pain and cognitive decline. The reporting period covers the three and nine months ended September 30, 2024. The company operates as a non-accelerated filer and smaller reporting company.

Key Financial Metrics

Note: The company has no revenue and no debt principal outstanding as of September 30, 2024. Related party accrued interest was settled during the period.

Material Changes vs. Prior Period

• Expense Reduction: General and Administrative (G&A) expenses decreased significantly year-over-year (from $3.8M to $3.1M for the nine months), primarily due to the absence of one-time IPO-related costs and debt issuance costs incurred in 2023.
• R&D Increase: Research and Development expenses increased from $1.2M to $2.4M for the nine months ended September 30, driven by initial payments for pre-clinical research projects.
• Interest Income: The company shifted from net interest expense in 2023 (due to debt costs) to net interest income of $127,564 in 2024, derived from money market accounts.
• Capital Structure: The company issued 1,485,263 shares via its At-The-Market (ATM) program, raising approximately $3.1 million in net proceeds. Total shares outstanding increased to 16,266,148.
• Operational Shift: The company terminated its physical office lease in April 2024, moving to a virtual office model, and ceased sharing management resources with related parties.

Outlook, Risks, and Management Commentary

• Liquidity and Going Concern: Management has raised a substantial doubt regarding the company's ability to continue as a going concern for the next 12 months. While cash on hand ($4.1M) is expected to fund operations through Q4 2025, the company explicitly states it does not have sufficient cash to support operations for at least 12 months from the filing date without additional financing.
• Product Strategy: MIRA-55 has been identified as the lead compound for the oral pharmaceutical marijuana program, superseding the previous MIRA1a molecule due to enhanced potency. Ketamir-2 remains in pre-clinical investigation.
• Financing Needs: Future funding is dependent on external equity or debt financing. The company maintains an effective shelf registration statement and an ATM agreement (capacity increased to $75M) to assist with liquidity needs.
• Internal Controls: Management concluded that disclosure controls and procedures were not effective as of the period end, though remediation plans involving new accounting personnel are underway.
• Risks: Key risks include reliance on third-party CROs for pre-clinical trials, potential delays due to geopolitical events (e.g., Israel-Hamas war), and the need for regulatory approval.

Investor Verification Checklist

• Cash Runway: Verify the specific monthly burn rate and confirm the timeline for the next capital raise given the "substantial doubt" disclosure.
• ATM Utilization: Monitor the pace of share issuance under the ATM program and the impact on shareholder dilution.
• Internal Controls: Review future filings for confirmation that the material weakness in internal controls has been remediated.
• Related Party Transactions: Scrutinize the terms of the $3.0M loan facility with MIRALOGX (Bay Shore Trust) and any future utilization.
• Pre-Clinical Milestones: Track progress on the Investigational New Drug (IND) application for Ketamir-2 and toxicology studies for MIRA-55.